Cargando…
The burden of CDI in the United States: a multifactorial challenge
Clostridioides difficile infection (CDI) affects approximately 500,000 patients annually in the United States, of these around 30,000 will die. CDI carries significant burdens including clinical, social and economic. While healthcare-associated CDI has declined in recent years, community-associated...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990004/ https://www.ncbi.nlm.nih.gov/pubmed/36882700 http://dx.doi.org/10.1186/s12879-023-08096-0 |
_version_ | 1784901863022264320 |
---|---|
author | Feuerstadt, Paul Theriault, Nicolette Tillotson, Glenn |
author_facet | Feuerstadt, Paul Theriault, Nicolette Tillotson, Glenn |
author_sort | Feuerstadt, Paul |
collection | PubMed |
description | Clostridioides difficile infection (CDI) affects approximately 500,000 patients annually in the United States, of these around 30,000 will die. CDI carries significant burdens including clinical, social and economic. While healthcare-associated CDI has declined in recent years, community-associated CDI is on the rise. Many patients are also impacted by recurrent C. difficile infections (rCDI); up to 35% of index CDI will recur and of these up to 60% will further recur with multiple recurrences observed. The range of outcomes adversely affected by rCDI is significant and current standard of care does not alter these recurrence rates due to the damaged gut microbiome and subsequent dysbiosis. The clinical landscape of CDI is changing, we discuss the impact of CDI, rCDI, and the wide range of financial, social, and clinical outcomes by which treatments should be evaluated. |
format | Online Article Text |
id | pubmed-9990004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99900042023-03-07 The burden of CDI in the United States: a multifactorial challenge Feuerstadt, Paul Theriault, Nicolette Tillotson, Glenn BMC Infect Dis Review Clostridioides difficile infection (CDI) affects approximately 500,000 patients annually in the United States, of these around 30,000 will die. CDI carries significant burdens including clinical, social and economic. While healthcare-associated CDI has declined in recent years, community-associated CDI is on the rise. Many patients are also impacted by recurrent C. difficile infections (rCDI); up to 35% of index CDI will recur and of these up to 60% will further recur with multiple recurrences observed. The range of outcomes adversely affected by rCDI is significant and current standard of care does not alter these recurrence rates due to the damaged gut microbiome and subsequent dysbiosis. The clinical landscape of CDI is changing, we discuss the impact of CDI, rCDI, and the wide range of financial, social, and clinical outcomes by which treatments should be evaluated. BioMed Central 2023-03-07 /pmc/articles/PMC9990004/ /pubmed/36882700 http://dx.doi.org/10.1186/s12879-023-08096-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Feuerstadt, Paul Theriault, Nicolette Tillotson, Glenn The burden of CDI in the United States: a multifactorial challenge |
title | The burden of CDI in the United States: a multifactorial challenge |
title_full | The burden of CDI in the United States: a multifactorial challenge |
title_fullStr | The burden of CDI in the United States: a multifactorial challenge |
title_full_unstemmed | The burden of CDI in the United States: a multifactorial challenge |
title_short | The burden of CDI in the United States: a multifactorial challenge |
title_sort | burden of cdi in the united states: a multifactorial challenge |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990004/ https://www.ncbi.nlm.nih.gov/pubmed/36882700 http://dx.doi.org/10.1186/s12879-023-08096-0 |
work_keys_str_mv | AT feuerstadtpaul theburdenofcdiintheunitedstatesamultifactorialchallenge AT theriaultnicolette theburdenofcdiintheunitedstatesamultifactorialchallenge AT tillotsonglenn theburdenofcdiintheunitedstatesamultifactorialchallenge AT feuerstadtpaul burdenofcdiintheunitedstatesamultifactorialchallenge AT theriaultnicolette burdenofcdiintheunitedstatesamultifactorialchallenge AT tillotsonglenn burdenofcdiintheunitedstatesamultifactorialchallenge |